Abstract: The present disclosure relates to methods of early identification and detection of neurotoxicity associated with the administration of chimeric antigen receptor (CAR) T cell therapy and mitigation strategies to reduce the occurrence and/or severity of treatment associated neurotoxicity.

Abstract: Systems for assessing and documenting changes in handwriting neurologic toxicity adverse events associated with a medical treatment (e.g., immune effector cell therapy) comprise a handwriting neurotoxicity grading criteria that defines the symptoms of at least one adverse event including micrographia, dysgraphia and agraphia. The handwriting neurotoxicity grading criteria may be included in a system for assessing immune effector cell associated movement and neurocognitive disorder, that comprises grading criteria for one or more of the symptom domains: handwriting impairment, gait impairment, other movement abnormalities of extremities, impairment in ability to perform ADLs, and impairment in expression or motivation.